November 30, 2007
Pharmaceuticals and the Economy of Medical Knowledge
Newspaper headlines over the past few months have documented the downfall of Avandia, a promising and widely prescribed drug for diabetes now linked to increased mortality from heart attacks. Roughly a million Americans were taking Avandia before the news of the side effects broke, and the public now wants to know why so many people were allowed to consume a potentially harmful compound for so long. Like Vioxx, Avandia has become a flash point in the public debate over the risks of new
This content is only for subscribers. You can gain access by purchasing a:
Print Subscription
Digital Subscription
Already have an account? Log In Now.
-
The Chronicle Review
-
Government
-
Advice
